Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel/carboplatin with or without lonafarnib for first-line epithelial ovarian cancer
ISRCTN51315091Phase 2Completed
- Sponsor
- AGO Research
- Start
- Sep 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and serous peritoneal carcinoma (PPSC) comparing Paclitaxel + carboplatin + lonafarnib with Paclitaxel + carboplatin (2 arms). Primary endpoint: Progression-free survival. Started Sep 2005; status: completed.
02
Drugs
lonafarnibpaclitaxelcarboplatin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)serous peritoneal carcinoma (PPSC)
Beyond the preview
Go deeper on ISRCTN51315091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN51315091.